Cellular phenotypic transitions in diabetic nephropathy: An update

被引:13
|
作者
Cao, Yiling [1 ]
Lin, Ji-Hong [2 ]
Hammes, Hans-Peter [2 ]
Zhang, Chun [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Nephrol, Wuhan, Peoples R China
[2] Heidelberg Univ, Med Fac Mannheim, Med Dept 5, Mannheim, Germany
基金
中国国家自然科学基金;
关键词
diabetic nephropathy; phenotypic transition; fibrosis; EMT; EndoMT; signaling pathway; EPITHELIAL-MESENCHYMAL TRANSITION; INTEGRIN-LINKED KINASE; CATENIN SIGNALING PATHWAY; GROWTH-FACTOR; MYOFIBROBLAST TRANSITION; MOLECULAR-MECHANISMS; BETA-CATENIN; INTERSTITIAL FIBROSIS; PODOCYTE DYSFUNCTION; RENAL FIBROSIS;
D O I
10.3389/fphar.2022.1038073
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetic nephropathy (DN) is a major cause of morbidity and mortality in diabetes and is the most common cause of end stage renal disease (ESRD). Renal fibrosis is the final pathological change in DN. It is widely believed that cellular phenotypic switching is the cause of renal fibrosis in diabetic nephropathy. Several types of kidney cells undergo activation and differentiation and become reprogrammed to express markers of mesenchymal cells or podocyte-like cells. However, the development of targeted therapy for DN has not yet been identified. Here, we discussed the pathophysiologic changes of DN and delineated the possible origins that contribute to myofibroblasts and podocytes through phenotypic transitions. We also highlight the molecular signaling pathways involved in the phenotypic transition, which would provide valuable information for the activation of phenotypic switching and designing effective therapies for DN.
引用
收藏
页数:15
相关论文
共 50 条
  • [11] Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update
    Bhattacharjee, Niloy
    Barma, Sujata
    Konwar, Nandita
    Dewanjee, Saikat
    Manna, Prasenjit
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 791 : 8 - 24
  • [12] Update on Diabetic Nephropathy: Core Curriculum 2018
    Umanath, Kausik
    Lewis, Julia B.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2018, 71 (06) : 884 - 895
  • [13] Update on diagnostic and prognostic biomarkers for diabetic nephropathy
    Herzog, Carolin
    Bose, Katrin
    Ganz, Maximilian J.
    Mertens, Peter R.
    Scurt, Florian G.
    DIABETOLOGIE, 2023, 19 (03): : 238 - 250
  • [14] The next generation of diabetic nephropathy therapies: An update
    Williams, ME
    Tuttle, KR
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2005, 12 (02) : 212 - 222
  • [15] Where are we in diabetic nephropathy: microRNAs and biomarkers?
    McClelland, Aaron
    Hagiwara, Shinji
    Kantharidis, Phillip
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2014, 23 (01) : 80 - 86
  • [16] Macrophages and Diabetic Nephropathy
    Tesch, Greg H.
    SEMINARS IN NEPHROLOGY, 2010, 30 (03) : 290 - 301
  • [17] Bioactive phytochemicals that regulate the cellular processes involved in diabetic nephropathy
    Parveen, Amna
    Jin, Mirim
    Kim, Sun Yeou
    PHYTOMEDICINE, 2018, 39 : 146 - 159
  • [18] Diabetic nephropathy: An update on pathogenesis and drug development
    Rao, Vikram Rao A. L. B. Vasanth
    Tan, Sean Hong
    Candasamy, Mayuren
    Bhattamisra, Subrat Kumar
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (01) : 754 - 762
  • [19] Dysfunction of Cellular Transporters and Predisposition to Diabetic Nephropathy
    Zerbini, Gianpaolo
    Gabellini, Daniela
    Ruggieri, Dora
    Maestroni, Anna
    CURRENT DIABETES REVIEWS, 2006, 2 (02) : 163 - 168
  • [20] Glomerular endothelial cells versus podocytes as the cellular target in diabetic nephropathy
    Maestroni, Silvia
    Zerbini, Gianpaolo
    ACTA DIABETOLOGICA, 2018, 55 (11) : 1105 - 1111